In the race to deliver life-saving therapies, the life sciences industry continually confronts unprecedented complexity and urgency. The challenge is clear: patients worldwide need novel drugs and vaccines, faster than ever before, without compromising reliable delivery, safety or quality.
Automation, combined with smart data management, has emerged as the foundation for this transformation, enabling pharmaceutical and biotech companies to accelerate discovery through commercial production, boost manufacturing agility, safeguard product quality, deliver a reliable supply of highquality products to market, and meet sustainability goals.
Almost 80% of biopharma leaders said in a 2023 Deloitte survey that their organisations needed to be more aggressive in adopting digital technologies, yet only 20% are making strides in digital maturity.1 Leaders with a datadriven mindset view data as a strategic asset, investing in automation and digitalisation – such as advanced process control, electronic batch records, innovative scheduling applications, integrated data platforms, digital twin simulation, machine learning and advanced analytics. These investments are already delivering significant benefits: reduced time-to-market, improved batch yields and enhanced regulatory compliance.
Automation: Advancing Five Strategic Priorities
There’s no question – a digital-first approach with smart data management is essential for building the next generation of biopharmaceutical plants. Digitally mature plants are best positioned to deliver new therapies at unprecedented speed and scale while reliably supplying the market. But how specifically is automation changing the game?
Let’s look at how automation addresses five critical priorities for the life sciences industry:
1. Pipeline Acceleration
Innovation in drug development is often hampered by manual, paper-based processes and siloed data. Automation transforms research and development by accelerating technology transfers, standardising processes, scaling recipes and boosting flexibility. This enables real-time data sharing, rapid iteration and seamless tech transfer from discovery to clinical manufacturing.
Automated pilot plants and flexible manufacturing suites improve process optimisation, empowering scientists to quickly scale up high-impact molecules, while advanced analytics flag potential failures. This acceleration can mean the difference between being first to market or missing critical patient needs.
2. Flexible Manufacturing
The increased use of contract development and manufacturing organisations and innovation in complex biologics demand manufacturing systems that can adapt in real time. It can be challenging for traditional, fixed production lines to switch between small batches of high-value drugs.
A modern automation platform specifically designed for the life sciences industry can help manufacturers manage contextualised data and translate processes, workflows and drug recipes between products, minimising downtime and risk.
Automation, powered by modular equipment, recipe-driven batch control and digital twins, enables rapid changeovers, remote configuration and continuous manufacturing. A modern automation platform specifically designed for the life sciences industry can help manufacturers manage contextualised data and translate processes, workflows and drug recipes between products, minimising downtime and risk.
3. Operational Integrity
Manual interventions introduce variability – a significant challenge in life sciences where meeting the production schedule is critical and product quality is non-negotiable. Automation enforces process control through closed-loop systems, real-time monitoring and electronic batch records.
